Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New migraine injector wins patient satisfaction in trial

NCT ID NCT01016834

Symptom relief Sponsor: Zogenix, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how satisfied people with migraines were using Sumavel DosePro, a needle-free injector for migraine medication. 246 adults who already used triptan drugs took part. The goal was to see if they liked this new method better than their usual treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

246 people

The number who actually took part.

Started

Nov 2009

Finished

Apr 2010

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * History of 2 to 6 migraine headaches per month * Migraines should have been present for at least 1 year with age at onset of migraine less than 50 years * History of 24 hours of freedom between migraine attacks * Current users of triptan medications * Able to distinguish interval or other non-migrainous headaches from typical migraine * General good health Exclusion Criteria: * History or symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes * Significant underlying cardiovascular diseases including uncontrolled hypertension * Hemiplegic or basilar migraine * History or diagnosis of severe hepatic or renal impairment * History of epilepsy or seizure or other serious neurologic condition * History of allergy, anaphylaxis, or hypersensitivity to sumatriptan or any of its components or similar drugs including sulphonamides * History of scleroderma (systemic sclerosis) * Pregnant or breastfeeding * Use of contraindicated prescription medications, monoamine oxidase inhibitors (MAO-A), selective serotonin reuptake inhibitors, or lithium agents

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Migraine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Migraine

Contacts and locations

Locations

  • Alpine Clinical Research

    Boulder, Colorado, 80304, United States

  • Arizona Research Center

    Phoenix, Arizona, 85023, United States

  • C. Phillip O'Carroll, MD, Inc

    Newport Beach, California, 92660, United States

  • California Medical Clinic for Headache

    Santa Monica, California, 90404, United States

  • Cleveland Clinic: Neurological Center for Pain

    Cleveland, Ohio, 33195, United States

  • Clinvest/A Division of Banyan Group, Inc

    Springfield, Missouri, 65807, United States

  • Comprehensive Neuroscience Inc

    St. Petersburg, Florida, 33716, United States

  • Comprehensive Neurosciences Inc

    Atlanta, Georgia, 30328, United States

  • Diamond Headache Clinic

    Chicago, Illinois, 60614, United States

  • Headache Wellness Center

    Greensboro, North Carolina, 27405, United States

  • Jefferson Headache Center

    Philadelphia, Pennsylvania, 19107, United States

  • Mercy Health Research

    St Louis, Missouri, 63141, United States

  • Meridian Clinical Research

    Omaha, Nebraska, 68134, United States

  • Michigan Head, Pain, & Neurological Institute

    Ann Arbor, Michigan, 48104, United States

  • Nashville Neuroscience Group

    Nashville, Tennessee, 37203, United States

  • Neurological Medicine

    Clarksville, Tennessee, 37043, United States

  • Neurology Specialists of Decatur

    Decatur, Georgia, 30033, United States

  • Regional Clinical Research Inc

    Endwell, New York, 13760, United States

  • Swedish Pain and Headache Center

    Seattle, Washington, 98104, United States

  • University Clinical Research Inc.

    Pembroke Pines, Florida, 33024, United States

  • University of Alabama Hospital, Dept. of Neurology

    Birmingham, Alabama, 35233, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.